Gilead Sciences, Inc. $GILD Shares Acquired by National Pension Service

Key Points

• National Pension Service increased its Gilead Sciences stake by 1.4% in the second quarter, adding 40,925 shares to own 3.06 million shares valued at approximately $386.9 million. Institutional investors and hedge funds collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year, and adjusted loss per share of $6.75, beating analyst expectations. Shares opened at $145.65, near the upper half of their 52-week range.
• The company declared a quarterly dividend of $0.82 per share, or $3.28 annualized, representing a 2.3% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $158.04.

National Pension Service lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,062,393 shares of the biopharmaceutical company's stock after buying an additional 40,925 shares during the quarter. National Pension Service owned approximately 0.25% of Gilead Sciences worth $386,903,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. California State Teachers Retirement System grew its stake in Gilead Sciences by 12,498.3% during the 2nd quarter. California State Teachers Retirement System now owns 241,168,657 shares of the biopharmaceutical company's stock worth $30,469,248,000 after purchasing an additional 239,254,365 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $15,393,785,000. State Street Corp grew its position in shares of Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock worth $7,393,921,000 after buying an additional 1,151,213 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock worth $3,399,734,000 after buying an additional 1,195,269 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock worth $2,837,948,000 after buying an additional 3,046,688 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $145.65 on Thursday. The company has a fifty day moving average of $137.96 and a two-hundred day moving average of $136.28. The company has a market capitalization of $180.60 billion, a PE ratio of -54.55 and a beta of 0.33. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.3%. Gilead Sciences's payout ratio is -122.85%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GILD shares. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a "sector perform" rating in a research note on Wednesday, August 5th. Truist Financial reduced their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a report on Tuesday, July 7th. Zacks Research raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 31st. Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 29th. Finally, Maxim Group raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 target price on the stock in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $158.04.

Insider Buying and Selling

In other news, Director Anthony Welters sold 18,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares of the company's stock, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the transaction, the insider owned 118,234 shares in the company, valued at approximately $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock valued at $14,495,820 in the last 90 days. Company insiders own 0.30% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.